Rahika® (capmatinib)
(Capmatinib) Oncology Oncology
Cataflam Drops® (Diclofenac Resinate)
(Diclofenac Resinate) Inflammation PharmaceuticalsVoltaren® slow release tablets (Diclofenac Sodium)
(Diclofenac Sodium) Inflammation PharmaceuticalsRitalin® (Methylphenidate HCl)
(Methylphenidate HCl) Neuroscience PharmaceuticalsRitalin® LA (Methylphenidate HCl)
(Methylphenidate HCl) Neuroscience PharmaceuticalsLioresal® (Baclofen)
(Baclofen) Musculoskeletal PharmaceuticalsZolgensma® (onasemnogene abeparvovec)
(onasemnogene abeparvovec) Gene TherapyJakavi® (ruxolitinib)
JAKAVI (ruxolitinib) JAKAVI (ruxolitinib) is the only licensed oral JAK1 and JAK2 inhibitor targeted therapy approved to treat adult patients with myelofibrosis (MF). 1 Indications: Myelofibrosis (MF) JAKAVI® (ruxolitinib) is indicated for the treatment...Piqray® (alpelisib - for Brunei only)
(Alpelisib) Oncology OncologyScemblix® (asciminib)
(Asciminib) Hematology Package Insert
×
Ask Speakers
×